Savings from Most-Favored-Nation Drug Pricing Policy

This executive summary details the Trump Administration’s Most-Favored-Nation (MFN) drug pricing framework, a policy designed to lower prescription drug costs for Americans by aligning them with the lowest prices paid in other developed nations.To date, the administration has secured voluntary MFN agreements with 17 of the world’s largest pharmaceutical manufacturers, with plans to expand this to most sole-source brand-name drugs and biologics.Prospective MFN (Future Launches): All new drugs launched in the U.S. will be priced comparably to other high-income countries. This applies to all U.S. markets, including private insurance.Projected Savings: $529 billion over the next 10 years.Existing Drugs: Manufacturers must provide MFN prices for existing drugs to state Medicaid programs.Projected Savings: $64.3 billion in combined federal and state savings over 10 years.The framework utilizes the TrumpRx.gov platform to provide massive out-of-pocket savings for drugs often purchased outside of traditional insurance:GLP-1 Drugs (Weight Loss): Uninsured patients are expected to save approximately $3,000 per year.Fertility Medications: Couples undergoing IVF are expected to save more than $6,000.Legislative Goal: The administration is working on legislation to ensure health insurers count these direct-to-consumer purchases toward a patient’s deductibles and out-of-pocket maximums.Because the administration successfully secured price reductions for GLP-1 drugs through MFN agreements, it has enabled a fiscally sustainable expansion of Medicare coverage specifically for anti-obesity treatments.The MFN framework is designed to work in tandem with U.S. trade policy to end foreign "freeriding" on American innovation:The Leverage: By committing to MFN pricing, the U.S. gives drug manufacturers leverage to negotiate higher prices with other wealthy nations.The Goal: To equalize global drug prices by simultaneously decreasing prices in the United States and increasing the contributions made by other developed countries to the pharmaceutical innovation enterprise.The administration is currently working with Congress to codify these voluntary agreements into law, ensuring that the price discounts become permanent features of the American healthcare system.The Dual Approach: Prospective vs. Existing DrugsDirect-to-Consumer Savings via TrumpRx.govMedicare ExpansionAlignment with "America First" Trade PolicyConclusion